TCRCure Biopharma Ltd. Conducts Investigator Meeting in Preparation for New Cervical Cancer Drug Study for TC-E202 (1st IND approved PD-1 antibody armed TCR-T compound in the world)

19 November 2021. TCRCure have received Investigational New Drug (IND) approval from the CENTER FOR DRUG EVALUATION, NMPA (the “CDE”)for the Phase 1/2 clinical study of Modified autologous T cells for targeting HPV and delivery of anti-PD-1 in the treatment of HPV-positive recurrence and metastasis cervical cancer.

In May 2019, TCRCure opened a new research and manufacturing site in the Los Angeles bioscience corridor. The 5000 square foot facility includes 1400 s.f. of GMP-compliant manufacturing space and 1000 s.f. of R&D space, plus additional flex space. Patient cell therapy products will be produced in a 600 square foot ISO 7 cleanroom according to cGMPs for cell-therapy manufacturing. It will be TCRCure’s major site for clinical-grade therapeutic production in the US.